Chai Discovery, an AI drug discovery startup, has secured major partnerships with pharmaceutical giants Pfizer and Eli Lilly to develop new antibody-based therapies using its advanced AI models. Valued at $1.3 billion, Chai recently launched its improved Chai-3 model, which significantly enhances the success rate and binding strength of designed antibodies, attracting Pfizer's interest. The company is also in talks to raise an additional $400 million at a $3.4 billion valuation, aiming to expand its collaborations and accelerate drug development. This progress highlights AI's growing impact on speeding up and improving the precision of drug discovery, potentially transforming the pharmaceutical industry.
